April 5 (Reuters) - The U.S. Food and Drug Administration on Friday allowed the expanded use of Johnson & Johnson and Legend Biotech's Carvykti cell therapy as an earlier treatment for patients with a type of blood cancer. (Reporting by Disha Mishra in Bengaluru; Editing by William Mallard)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
45.37 USD | -2.16% | +5.17% | -24.42% |
May. 15 | Legend Expects to Log Profit in 2026 | MT |
May. 14 | HC Wainwright Adjusts Price Target on Legend Biotech to $86 From $87, Keeps Buy Rating | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
154.2 USD | -0.03% | +2.81% | 371B | ||
45.37 USD | -2.16% | +5.17% | 8.45B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.42% | 8.45B | |
+8.73% | 114B | |
+10.88% | 104B | |
-12.79% | 22.41B | |
-1.11% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.97% | 17.89B | |
+7.88% | 14.28B | |
+36.43% | 12.55B |
- Stock Market
- Equities
- LEGN Stock
- News Legend Biotech Corporation
- U.S. FDA approves expanded use of J&J's cancer cell therapy